Dipeptidylpeptidase

Other Names

ADAbpAdenosine deaminase binding proteinAdenosine deaminase complexing protein 2Amino acyl-prolyl dipeptidyl aminopeptidaseCD26DAP-IVDipeptidyl aminopeptidase IVDipeptidyl Peptidase IVDipeptidyl-peptide hydrolaseDP4DPP IV/CD26DPP-IVDPP4EC 3.4.14.5FAPβGly-Pro naphthylamidaseGlycoprotein GP110Glycylproline aminopeptidaseGlycylprolyl aminopeptidaseGlycylprolyl dipeptidylaminopeptidaseGP110Leukocyte antigen CD26Lymphocyte antigen CD26Pep XPostproline dipeptidyl aminopeptidase IVT cell triggering molecule Tp103Tp103X-PDAPX-prolyl dipeptidyl aminopeptidaseXaa-Pro-dipeptidyl-aminopeptidase

Synopsis

Dipeptidyl Peptidase IV (DPP-IV): A Comprehensive Reference

1. Identity, Nomenclature, and Forms

1.1 Chemical and Systematic Names

First described in 1966 by Hopsu-Havu and Glenner, dipeptidyl-peptidase IV (DPP-IV; EC 3.4.14.5), also originally known as lymphocyte cell surface marker CD26 or as the adenosine deaminase (ADA)-binding protein, is a 110 kDa glycoprotein existing primarily as a membrane-anchored cell-surface enzyme. It is catalogued under multiple synonymous names across biochemical and immunological literature. These include dipeptidyl aminopeptidase IV, CD26, glycoprotein GP110, glycylproline aminopeptidase, T cell triggering molecule Tp103, X-PDAP, THAM, and adenosine deaminase binding protein (ADAbp).

DPP-IV (EC 3.4.14.5, also known as DPP4, DP4, DAP-IV, adenosine deaminase complexing protein 2, adenosine deaminase binding protein (ADAbp) or CD26) is a 766-residue, 240 kDa protein that is a highly specific membrane-bound non-classical serine aminodipeptidase.

1.2 Molecular Structure

Native DPP-IV is a ubiquitous type II transmembrane glycoprotein and a serine protease of the S9 prolyl-oligopeptidase family. Each subunit comprises two structural domains: the N-terminal eight-bladed β-propeller with open Velcro topology and the C-terminal α/β-hydrolase domain. The catalytic triad of DPP-IV (Ser642, Asp720 and His752) is located in the peptidase domain or catalytic domain of DPP-IV.

It is a glycoprotein having a molecular weight of 110 kDa commonly found on the surface of cells in many organs such as the kidney, liver, colon, placenta, prostate, skin, lymphocytes and endothelial cells. A soluble form is present in plasma and other body fluids.

1.3 Natural Biological Source and Forms Relevant to Supplementation

DPP-IV in the context of the dietary supplement market encompasses two distinct but related categories:

Exogenous DPP-IV enzyme supplements: Products marketed as "DPP-IV enzyme" supplements contain a DPP-IV-like activity often sourced from microbes such as Aspergillus species, intended to help break down proline-rich segments of dietary proteins. Gluten and casein contain many proline residues, which resist common human proteases, so the idea is that a proline-specific enzyme taken with meals may reduce residual peptides before they reach the small intestine.
Food-derived DPP-IV inhibitory peptides: Peptides with DPP-IV inhibitory activity have been identified in a variety of food proteins. These are naturally occurring bioactive compounds found in dietary sources (particularly dairy, fish, and legumes) that act to suppress the activity of the body's own DPP-IV enzyme, thereby modulating incretin hormone levels and glycemic regulation.

Dipeptidyl Peptidase IV (DPP-4, also known as CD26) is a membrane-anchored and soluble serine protease that inactivates regulatory peptides such as GLP-1 and GIP, modulates immune signaling, and is the pharmacologic target of the DPP-4 inhibitor class of antidiabetic drugs (gliptins).

1.4 Supplement Forms and Preparations

In supplement form, DPP-IV enzymes are used to assist individuals who have difficulty digesting gluten (gliadin) and casein—proteins commonly found in wheat and dairy. These preparations are typically dispensed as oral capsules or tablets designed for peri-meal consumption. The microbial DPP-IV enzyme most commonly encountered in commercial supplements is derived from Aspergillus oryzae. Recombinant prolyl-dipeptidyl-peptidase (DPP-IV) from Aspergillus oryzae has been characterized and produced commercially.

In 2009, Ehren et al. found that more complete clearance of gluten epitopes could be achieved by combining aspergillopepsin with dipeptidyl peptidase IV (DPP-IV) from Aspergillus oryzae. Dipeptidyl peptidase IV is a candidate used to support gluten digestion. DPP-IV is part of the exopeptidase family and often used in foods and supplements as a debittering agent.

On the inhibitory-peptide side, food-derived DPP-IV inhibitory peptides are found in a wide range of natural sources. Known natural DPP-IV inhibitors derived from natural products include peptides derived from a water-soluble fraction of cheese, peptides derived from a milk protein, enzymatically decomposed products of an azuki bean or a kidney bean, peptides derived from gelatin, and peptides derived from enzymatically decomposed products of gelatin extracted from salmon skin.

2. Historical and Traditional Context

DPP-IV was identified and studied in the mid-20th century during advances in protein chemistry and immunology. Unlike many plant-based enzymes (such as bromelain or papain), DPP-IV has no known use in ancient herbal traditions because it is a highly specific, modern, purified enzyme discovered through biochemical research. The application of DPP-IV supplements in natural health emerged in the early 2000s, particularly through autism research and gluten-sensitive populations.

While DPP-IV itself has no pre-modern history, certain plants and foods now understood to inhibit DPP-IV enzymatic activity have long historical use in traditional medicine for conditions related to blood sugar. Chinese and Indian turmeric (Curcuma longa Linn.) has been used in multiple functions for long periods and demonstrated effects for anti-cancer, anti-oxidation, and inflammation. Some articles have also indicated that curcumin exhibited lower blood sugar function in animal models and human trials.

Glycyrrhiza uralensis (licorice) is widely consumed and used as medicine, and has more recently been identified as having DPP-IV inhibitory activity through its constituent chalcones.

The supplement-specific use of purified DPP-IV enzyme began gaining commercial traction in the early 2000s, driven largely by two research threads: the "opioid excess hypothesis" of autism spectrum disorder (ASD), and the parallel discovery of pharmaceutical DPP-IV inhibitor drugs (gliptins) for type 2 diabetes, which prompted the food science community to seek natural analogs.

3. Key Constituents, Active Compounds, and Mechanisms of Action

3.1 The Endogenous DPP-IV Enzyme: Mechanism

DPP-IV/CD26 is a cell-surface protease belonging to the prolyl oligopeptidase family. It selectively removes the N-terminal dipeptide from peptides with proline or alanine in the second position. This exopeptidase activity is highly selective: DPP-IV has a serine type mechanism of protease activity, cleaving off dipeptides from the amino-terminus of peptides with proline or alanine at the penultimate position; in addition, the slow release of dipeptides of the type X-Gly or X-Ser is reported for some naturally occurring peptides.

This multifunctional enzyme is implicated in several biological processes, including the degradation of chemokines, neuropeptides, and incretin hormones such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both the incretin hormones have the potential to stimulate insulin secretion from the islet beta-cell in a glucose-dependent manner.

3.2 The Incretin Pathway: Primary Metabolic Mechanism

Incretins are naturally occurring gut-derived peptides, such as GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), which are released rapidly in response to the consumption of food. DPP-IV is a ubiquitous aminodipeptidase that cleaves incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), resulting in a loss in their insulinotropic activity.

The inhibition of DPP-4 activity increases the level of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, which in turn reduces hyperglycemia by activating insulin secretion and inhibiting glucagon secretion. By cleaving and inactivating GLP-1, DPP-IV reduces insulin secretion and promotes glucagon release, thereby contributing to elevated blood glucose levels. Consequently, inhibiting DPP-IV activity has emerged as a validated therapeutic strategy for type 2 diabetes mellitus (T2DM), as it prolongs the half-life and enhances the activity of endogenous GLP-1, improving glycemic control.

3.3 Non-Enzymatic and Immune Functions

Apart from its catalytic activity, DPP-IV interacts with several proteins—including adenosine deaminase, the HIV gp120 protein, fibronectin, collagen, the chemokine receptor CXCR4, and the tyrosine phosphatase CD45. DPP-IV is expressed on a specific set of T lymphocytes, where it is up-regulated after activation. It is also expressed in a variety of tissues, primarily on endothelial and epithelial cells.

On immune cells, CD26/DPP-4 influences how strongly T cells become activated and how they migrate to tissues, by both enzymatic actions (cutting chemokines) and non-enzymatic interactions (binding to proteins such as adenosine deaminase).

DPP-IV has been proposed as a diagnostic or prognostic marker for various tumors, hematological malignancies, immunological, inflammatory, psychoneuroendocrine disorders, and viral infections.

3.4 Food-Derived DPP-IV Inhibitory Compounds

A range of natural compounds from food and botanical sources have been identified as DPP-IV inhibitors. These span several chemical classes:

Dietary protein-derived bioactive peptides: Among DPP-IV inhibitory peptides, those from milk have been the most extensively studied, and many of the more than 150 known DPP-IV inhibitory peptides that have been reported can be found in the sequence of casein and whey proteins.
Plant phenolics and polyphenols: According to chemical structure, top docking candidates with DPP-IV inhibitory potential include phenolics (curcumin, syringic acid, and resveratrol), flavonoids (catechin, quercetin, and kaempferol), and others including shikimic acid, berberine, and rutin.
Licorice chalcones: In silico studies showed that licochalcone A and licochalcone B bind tightly to the catalytic site of DPP-4 and have 11 amino acid residue interactions in common with the control inhibitor sitagliptin.
Plant extracts more broadly: Eighteen plants showed inhibition against DPP-IV as proven by in silico, in vitro, and in vivo studies, with only ten plants reported for efficacy in clinical studies. Several plant-based DPP-IV inhibitors—including Allium sativum, Morus alba, Curcuma longa, Pterocarpus marsupium, and Taraxacum officinale—have established their functional role in inhibiting DPP-IV and have proven their effectiveness through human studies.

3.5 Structural Basis of Substrate Specificity

The crystal structure of the free form of the enzyme reveals two potential channels through which substrates could access the active site—a so-called propeller opening, and side opening. The crystal structure of the DPP-IV/Neuropeptide Y complex suggests that bioactive peptides utilize the side opening unique to DPP-IV to access the active site. The active site includes key residues: His740, Ser630, Tyr631, Tyr547, Tyr666, Tyr662, Arg125, Glu205, Glu206, and Phe357.

4. Scientific Evidence by Area of Use

4.1 Gluten and Casein Digestion

Proposed mechanism: Peptidase, specifically dipeptidyl peptidase IV (DPP-IV), is a serine protease enzyme that breaks down specific peptides in the body by removing dipeptides from the N-terminal end of proteins—particularly when proline or alanine is in the penultimate position. Because gluten and casein are unusually rich in proline residues that ordinary human digestive enzymes cannot efficiently cleave, supplemental DPP-IV activity has been proposed as an aid.

In vitro evidence: A 2009 study by Ehren et al. (PubMed PMID: 19621078) combined Aspergillus-derived aspergillopepsin (ASP) with DPP-IV. ASP markedly enhanced gluten digestion relative to pepsin and cleaved recombinant alpha2-gliadin at multiple sites. When used alone, neither ASP nor DPP-IV efficiently cleaved synthetic immunotoxic gluten peptides. This lack of specificity for gluten was especially evident in the presence of casein, a competing dietary protein. However, supplementation of ASP with DPP-IV enabled detoxification of moderate amounts of gluten in the presence of excess casein and in whole-wheat bread.

Neither ASP nor DPP-IV efficiently cleaved synthetic immunogenic gluten peptides when used alone, but when ASP was combined with DPP-IV or with EP-B2 (ALV-002, as a component of ALV-003), it exhibited only modest to moderate activity to reduce immunogenic gluten.

pH and stability considerations: Aspergillus oryzae DPP-IV released into the stomach is stable to acidic pepsin but inactive at stomach pH. It is therefore likely that DPP-IV enzymes released in the stomach pass into the pH-neutral environment of the duodenum/small intestine, where, unless exhausted or inhibited in the stomach, they should remain optimally active.

Comparative supplement performance: A peer-reviewed study published in Frontiers in Nutrition (2021, PMC8688929) compared nine commercial digestive supplements containing DPP-IV and related enzymes. The DPP-IV supplements tested (supplements 5, 6, 7, and 8) and a fungal/bacterial-containing supplement (9) had little activity at either pH tested with the Gluten-Tec ELISA system. For an enzyme supplement to be useful in alleviating symptoms induced by celiac immuno-toxic gluten peptides, all ingested peptides should be completely cleaved. This study points to a significant practical limitation of current DPP-IV enzyme supplements marketed for gluten digestion.

Clinical call to action: The authors of the Ehren et al. in vitro study concluded that clinical studies are warranted to evaluate whether a fixed-dose ratio combination of ASP and DPP-IV can provide near-term relief for celiac patients suffering from inadvertent gluten exposure. As of the available literature, large-scale, controlled human clinical trials specifically testing oral DPP-IV enzyme supplements for gluten detoxification remain limited. Evidence strength: preliminary; primarily in vitro and small mechanistic studies. No robust human RCTs have demonstrated clinical protection against mucosal injury in celiac disease.

4.2 Autism Spectrum Disorder (ASD) and the Opioid Excess Hypothesis

Opioid peptides released during digestion of dietary proteins such as casein were suggested to contribute to autism development, leading to the announcement of the opioid excess hypothesis of autism. This hypothesis centers on the enzyme proline dipeptidyl peptidase-4 (DPP-IV; EC 3.4.14.5) and its exogenous substrate β-casomorphin-7 (BCM7) in autism etiology.

Several animal studies have shown that inhibition of gut peptidases, specifically DPP-IV, results in increased levels of urinary peptides of dietary origin. Many of the urinary peptides detected from children with ASD can be classified as exorphins (exogenous opioids) and include casomorphins, gliadinomorphins, gluteomorphins, deltorphin, and dermorphin.

A Polish research group (Fiedorowicz et al., 2018; PMC6356206) studied 86 children with ASD and 51 healthy controls, measuring DPP-IV and BCM7 concentrations in serum and urine. The study included measurements of DPP-IV and BCM7 concentrations in serum and urine, analyzed with ELISA assays, and measured DPP-IV activity by colorimetric test. The effect of opioid peptides from hydrolyzed bovine milk on DPP-IV gene expression in peripheral blood mononuclear cells (PBMC) in autistic and healthy children was determined. The study included 51 healthy children and 86 children diagnosed with autism spectrum disorder.

Medicinally, DPP-IV enzyme supplements are most often used to support individuals with gluten sensitivity, autism spectrum disorders, or digestive issues involving incomplete protein breakdown. However, the evidence base for DPP-IV supplementation as a treatment for ASD is currently limited to mechanistic hypotheses and observational data; no large-scale, double-blind, placebo-controlled human clinical trials of DPP-IV enzyme supplementation for ASD have been reported in the peer-reviewed literature. The commercial use is based on the logic that supplementing intestinal DPP-IV activity may reduce systemic absorption of opioid-active peptides, but this causal chain has not been clinically confirmed.

4.3 Glycemic Regulation and Type 2 Diabetes

This is the most extensively researched area related to DPP-IV. Research here spans two tracks: (a) pharmaceutical DPP-IV inhibitors (gliptins), which are established prescription drugs; and (b) food-derived DPP-IV inhibitors, which are the focus of nutritional science and are still largely pre-clinical.

Pharmaceutical context (established clinical evidence): Of the twelve classes of glucose-lowering drugs currently available for the management of diabetes, inhibitors of the enzyme DPP-IV are among the newest agents to have been introduced to the type 2 diabetes pharmacopeia. These synthetic inhibitors, which can be used either as monotherapy or in combination with other anti-diabetic drugs, exert their glucose-lowering effect by preventing the degradation of gut-derived hormones that play a pivotal role in glycemic regulation. Vildagliptin, saxagliptin, sitagliptin, and alogliptin are approved antidiabetic agents by the United States and Europe.

Food-derived DPP-IV inhibitors — dairy peptides: Multiple studies have shown that both whey protein and casein have properties that stimulate the release of insulin and lower glucose levels in both healthy individuals and those with type 2 diabetes mellitus. Extensive research conducted in the dairy industry over the past two decades has demonstrated that milk proteins contain peptides possessing biological features that can mitigate diabetes. Preclinical and clinical research has found some excellent peptides with superior efficacy and safety.

Milk protein-derived DPP-IV inhibitory peptides have a strong prospectus as dietary supplements to manage prediabetes and diabetes. Considering the potential reported, milk protein-derived DPP-IV inhibitory peptides could be used as a monotherapy to treat prediabetes and as an adjunct therapy for treating diabetes along with other medications. However, a couple of complete clinical studies involving human subjects are required to prove the efficacy of this supplement beyond doubt.

Bioavailability challenges: A key scientific concern is whether orally ingested DPP-IV inhibitory peptides survive gastric transit and reach systemic circulation intact. While much attention has been given to the production and identification of peptides with DPP-IV inhibitory activity from food proteins, particularly dairy proteins, little is known on the bioavailability of these molecules. A Caco-2 cell model study (Lacroix et al., 2017) investigated the stability and transport of five identified milk-derived peptides across a model intestinal epithelium, finding variable stability and transport rates depending on peptide sequence.

A comparative in vitro/in vivo study (PMC9369239) tested seven protein sources. The DPP-IV-inhibitory potential of seven proteins from diverse origins was compared for the first time in vitro and in vivo in rat plasma after intestinal barrier passage. The DPP-IV-inhibitory potentials of bovine hemoglobin, caseins, chicken ovalbumin, fish gelatin, and pea proteins were determined in rat plasma thirty minutes after oral administration.

In vivo animal evidence: Evidence demonstrates that several oligopeptides can act as endogenous inhibitors of DPP-IV, and whey protein administration in mice reduces DPP-IV activity in the proximal small intestine, the predominant site of GLP-1 secretion.

Evidence strength for food-derived DPP-IV inhibitory peptides in diabetes: The evidence is primarily in vitro and animal-based. While the mechanistic rationale is well established and some human clinical data on dairy protein consumption and glucose regulation exist, dedicated clinical trials of isolated, purified DPP-IV inhibitory peptides as supplements for glycemic control in humans remain limited. This area is one of active and ongoing research.

4.4 Natural Phenolic Compounds as DPP-IV Inhibitors

A body of research has used molecular docking, in vitro enzyme assays, and animal models to identify dietary phenolic compounds with DPP-IV inhibitory properties.

Curcumin: After screening, curcumin, syringic acid, and resveratrol were found to have high affinity with DPP-IV enzymes. In enzymatic tests, curcumin and resveratrol showed potential inhibition of DPP-IV. In vitro assays showed curcumin inhibited DPP-IV activity in Caco-2 cells and ERK phosphorylation in C2C12 cells. The results revealed that curcumin and resveratrol had inhibitory effects, with the inhibitory rate of curcumin reaching up to 50%, which was higher than for P32/98 and resveratrol.

A human clinical study of curcumin for T2DM was identified in a review published in Drug Design, Development and Therapy (2023): a study in fifty-three T2DM patients treated with either 1500 mg of curcumin or a placebo capsule 3 times per day for 10 weeks resulted in considerably reduced mean values for BMI, abdominal circumference, and fasting plasma glucose in curcumin-treated patients. However, HOMA-IR, HbA1c, insulin, and pancreatic β-cell function demonstrated no difference. Notably, the DPP-IV inhibitory mechanism was proposed but not directly confirmed as the operative pathway in this human trial.

Quercetin, berberine, and other flavonoids: Phytochemicals such as curcumin, resveratrol, luteolin, apigenin, and flavone were discovered to have strong affinity to DPP-IV enzymes in molecular docking and enzymatic studies. Quercetin, a flavonoid, is known to inhibit the DPP-IV enzyme based on virtual docking results. These findings are predominantly in silico and in vitro; human clinical trials specifically investigating flavonoid DPP-IV inhibition are very limited.

No natural compound matches the potency of pharmaceutical DPP-IV inhibitors at typical dietary doses. Evidence in this area is primarily preliminary, mechanistic, and derived from in vitro and animal models.

4.5 Immunological and Oncological Associations

DPP-IV/CD26 has been extensively studied as a biomarker and functional participant in immunity and cancer biology. These findings are not related to supplement use but are scientifically important for understanding the enzyme's broader physiological role.

A marker of activated T cells, CD26 expression is upregulated during T-cell activation. Some of the main substrates of this enzyme are key chemokines involved in immune cell migration, and both soluble and cell-surface CD26 can bind adenosine deaminase (ADA), an enzyme involved in the metabolism of immunosuppressor extracellular adenosine. T cells enriched in CD26 expression exist, and in mouse tumor models, tumor-infiltrating lymphocytes exhibited heightened percentages of CD26+ cells correlating with tumor regression.

Patients with hematological malignancies such as non-Hodgkin lymphoma, Hodgkin lymphoma, leukemia, plasmacytoma, and multiple myeloma have been studied; significantly decreased DPP4 activity and percentages of CD26+ lymphocytes have been observed in comparison with healthy individuals. Many malignant breast cancer patients in early stages exhibit higher DPP4 activity than controls.

Soluble CD26 has been employed as a biomarker in the follow-up after curative resection of colorectal cancer for the early detection of tumor recurrence. These applications are purely in the domain of clinical diagnostics and are not connected to commercially available dietary supplements.

5. Body Systems and Health Areas Associated with DPP-IV

Gastrointestinal system: DPP-IV plays a vital role in both digestion and immune regulation, and is produced in the small intestine, kidneys, and immune cells. In the gut, DPP-IV is expressed on the brush border of intestinal epithelial cells, where it participates in the terminal digestion of proline-containing dietary peptides.
Endocrine/Metabolic system: As the enzyme that inactivates the incretin hormones GLP-1 and GIP, DPP-IV is a central regulator of postprandial glucose homeostasis and insulin secretion.
Immune system: CD26/DPP-IV has a role in the regulation of the human immune system. It modulates T-cell activation and chemokine processing.
Renal system: The enzyme DPP-IV is present in a variety of tissues, particularly epithelial tissues of the liver, kidney, and small intestine, and exists as a soluble circulating form.
Neurological/Psychiatric: DPP-IV processes neuropeptides and has been implicated in psychoneuroendocrine disorders. The opioid excess hypothesis of ASD centers on DPP-IV's role in cleaving casomorphins and gliadinomorphins derived from food proteins.
Oncology: Soluble DPP-IV (sCD26) is an active area of research as a cancer biomarker. CD26 expression has been characterized on various cancers such as malignant pleural mesothelioma, colorectal cancer, hepatocellular carcinoma, renal cell carcinoma, lung cancer, prostate cancer, thyroid cancer, gastrointestinal stromal tumor, and selected hematologic malignancies.

6. Dosage Forms and Reported Dosages

6.1 Exogenous DPP-IV Enzyme Supplement Products

Commercial DPP-IV enzyme supplements are supplied as oral capsules intended for peri-meal use. These products typically contain fungal-derived DPP-IV activity measured in activity units rather than milligrams of protein. The activity is expressed as DPP-IV Units (DPP-IV U). No standardized evidence-based dosage has been established through human clinical trials for these preparations. ASP and DPP-IV are widely used in the food and feed industry as dietary supplements.

6.2 Food-Derived DPP-IV Inhibitory Peptides: Research Dosages

In the in vitro research context, potency is typically expressed as IC₅₀ (the concentration required to inhibit 50% of DPP-IV activity). The most potent camel milk protein-derived DPP-IV inhibitory peptides, LPVP and MPVQA, had DPP-IV half-maximal inhibitory concentrations (IC₅₀) of 87.0 ± 3.2 and 93.3 ± 8.0 µM, respectively.

6.3 Curcumin (as a DPP-IV Inhibitory Natural Compound)

In a published human study of curcumin in T2DM referenced in a 2023 review: fifty-three T2DM patients were treated with either 1500 mg of curcumin or a placebo capsule 3 times per day for 10 weeks. This is the dose as reported in the source; this dose was used in the context of studying overall blood glucose effects, not DPP-IV inhibition specifically as a primary endpoint.

6.4 Pharmaceutical DPP-IV Inhibitors (Prescription Reference)

Therapeutic modulation of DPP-IV is achieved clinically with prescription DPP-4 inhibitors (e.g., sitagliptin 100 mg, linagliptin 5 mg). These are prescription-only drugs and are presented here solely as pharmacological reference points for understanding the enzyme's role, not as dietary supplements.

7. Safety Considerations and Interactions

7.1 Safety of Microbial-Derived DPP-IV Enzyme Supplements

Most DPP-IV and prolyl endopeptidase supplements are produced by Aspergillus fermentation. People with mold sensitivities should discuss with a clinician and consider cautious trials, stopping if they develop rash, itching, or breathing difficulty.

Aspergillus oryzae and Aspergillus niger have a long history of safe use in food processing. The safety profiles of these microbial enzyme-producing organisms are reviewed in the scientific literature referenced by the Enzyme Technical Association and peer-reviewed regulatory toxicology publications. However, the specific safety profile of purified fungal DPP-IV used as a dietary supplement in human populations has not been extensively evaluated in dedicated clinical safety trials.

7.2 Celiac Disease: Critical Limitation

DPP-IV is not a replacement for a gluten-free diet in celiac disease; it may reduce the impact of accidental gluten exposure by breaking down immunogenic peptides before they trigger an inflammatory response. However, the experimental evidence shows significant limitations: individuals with celiac disease should not rely on enzymes to "cover" intentional gluten consumption. Even when endopeptidases break down a portion of gluten peptides, trials have not shown consistent protection against mucosal injury or immune activation. Strict avoidance remains standard of care.

7.3 Interaction with Prescription DPP-4 Inhibitor Drugs

Digestive DPP-IV enzyme supplements are not anti-diabetic drugs and have no proven systemic effect on incretin hormones when taken orally. If taking prescription DPP-4 inhibitors, digestive enzyme supplements can generally be considered separately, but coordination with a prescriber is warranted to avoid misunderstandings about their distinct roles.

Although most synthetic DPP-IV inhibitors (the prescription drugs) are generally well-tolerated, some side effects have been reported, including nasopharyngitis, headaches, and urinary infections. These are drug-class effects of the pharmaceutical inhibitors and do not directly apply to dietary enzyme supplement use.

7.4 Incomplete Clinical Safety Data for Isolated Peptide Supplements

There is currently a lack of a comprehensive guideline for assessing the safety of peptide-like functional meals and isolated bioactive peptide supplements. This underscores that while food-derived DPP-IV inhibitory peptides are generally considered to derive from generally recognized as safe (GRAS) food sources, the long-term safety profile of concentrated, isolated DPP-IV inhibitory peptide preparations has not been established through formal toxicological or clinical safety studies in humans.

7.5 Enzyme Supplement Activity and pH Stability

A practical safety-adjacent concern is that DPP-IV enzyme preparations from Aspergillus oryzae are inactive at the acidic pH of the stomach. Aspergillus oryzae DPP-IV released into the stomach is stable to acidic pepsin but inactive at stomach pH. It is therefore likely that DPP-IV enzymes released in the stomach pass into the pH-neutral environment of the duodenum/small intestine, where their activity is recovered. This has implications for product formulation and the window of activity in the gastrointestinal tract.

8. Current State of Evidence and Research Gaps

The scientific literature on DPP-IV in the dietary supplement context can be summarized along a spectrum of evidence strength:

Well-established (pharmacology/biochemistry): The mechanism of DPP-IV's role in incretin hormone inactivation and glucose metabolism is thoroughly characterized. The pharmaceutical DPP-4 inhibitor drug class is robustly supported by large-scale clinical trials.
Moderately supported (preclinical): In vitro and animal studies demonstrate that food-derived peptides from dairy, fish, and plant proteins can inhibit DPP-IV activity and reduce postprandial glycemia in animal models. The structural basis for these interactions is well understood.
Preliminary (human clinical): Compelling findings from in vitro as well as animal and clinical studies have shown that some dietary factors, such as peptides and phenolic compounds, can help regulate blood glucose levels. However, dedicated human RCTs of isolated food-derived DPP-IV inhibitory peptides as stand-alone supplements are limited, and questions of bioavailability, effective dose, and long-term efficacy in humans remain open.
Preliminary/unconfirmed (supplement-specific use): The use of microbial DPP-IV enzyme supplements for gluten digestion, ASD, or gluten sensitivity is based on mechanistic reasoning and limited in vitro data. DPP-IV supplements demonstrated little activity at relevant pH values in comparative testing of commercial products. Large human RCTs are absent from the peer-reviewed literature.

References

Health Conditions

Health conditions that Dipeptidylpeptidase may help support.

No conditions available.

Body Systems

Body systems that Dipeptidylpeptidase may help support.

No body systems available.